Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary sclerosing cholangitis (PSC) established by all of the following criteria:~  * Alkaline phosphatase \>1.5x upper limit of normal for at least 6 months prior to study enrollment~ * Cholangiography demonstrating intrahepatic and/or extrahepatic biliary dilation, beading, and/or strictures consistent with PSC~ * Liver histology (if available for review) consistent with or diagnostic of PSC~* Women of child-bearing potential willing to use birth control for the duration of the study.~Exclusion Criteria:~* Treatment with any investigational agents within three months prior to or during the study~* Treatment with systemic antibiotics, azulfidine, systemic corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, tacrolimus, or vitamin E within three months prior to or during the study.~* Concomitant treatment with NSAIDS, antiplatelet agents, antihyperlipidemics, and anticoagulant warfarin.~* Anticipated need for liver transplant within one year as determined by Mayo PSC risk score (\<80% one-year survival without transplant)~* Active drug or alcohol use~* Findings suggestive of liver disease of an alternative or concomitant etiology, such as chronic alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis, or secondary sclerosing cholangitis (e.g., post-liver transplantation biliary stricture)~* Pregnancy or lactation~* Any condition that, in the opinion of the investigator, would interfere with the patient's ability to complete the study safely or successfully.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Curcumin (Type: EXPERIMENTAL): Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.

Based on this trial design, predict the completion outcome and termination type (if applicable).